Journal article
Ozurdex in age-related macular degeneration as adjunct to ranibizumab (The OARA Study)
Abstract
OBJECTIVE: To evaluate the utility of dexamethasone intravitreal implant (DXI; Ozurdex; Allergan, Irvine, Calif.) in combination with ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) versus ranibizumab monotherapy on visual acuity (VA) and anatomical outcomes in a neovascular age-related macular degeneration (nAMD) cohort.
DESIGN: Multicentred, single-blinded, pilot randomized control trial.
Authors
Chaudhary V; Barbosa J; Lam W-C; Mak M; Mavrikakis E; P SMM
Journal
Canadian Journal of Ophthalmology, Vol. 51, No. 4, pp. 302–305
Publisher
Elsevier
Publication Date
August 2016
DOI
10.1016/j.jcjo.2016.04.020
ISSN
0008-4182